Prevalidation of Salivary Biomarkers for Oral Cancer Detection
Background: Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three...
Saved in:
Published in | Cancer epidemiology, biomarkers & prevention Vol. 21; no. 4; pp. 664 - 672 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
01.04.2012
|
Subjects | |
Online Access | Get full text |
ISSN | 1055-9965 1538-7755 1538-7755 |
DOI | 10.1158/1055-9965.EPI-11-1093 |
Cover
Abstract | Background: Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three proteins previously reported as biomarkers are capable of discriminating patients with oral squamous cell carcinomas (OSCC) from healthy subjects in independent cohorts and by a National Cancer Institute (NCI)-Early Detection Research Network (EDRN)-Biomarker Reference Laboratory (BRL).
Methods: Three hundred and ninety-five subjects from five independent cohorts based on case controlled design were investigated by two independent laboratories, University of California, Los Angeles (Los Angeles, CA) discovery laboratory and NCI-EDRN-BRL.
Results: Expression of all seven mRNA and three protein markers was increased in OSCC versus controls in all five cohorts. With respect to individual marker performance across the five cohorts, the increase in interleukin (IL)-8 and subcutaneous adipose tissue (SAT) was statistically significant and they remained top performers across different cohorts in terms of sensitivity and specificity. A previously identified multiple marker model showed an area under the receiver operating characteristic (ROC) curve for prediction of OSCC status ranging from 0.74 to 0.86 across the cohorts.
Conclusions: The validation of these biomarkers showed their feasibility in the discrimination of OSCCs from healthy controls. Established assay technologies are robust enough to perform independently. Individual cutoff values for each of these markers and for the combined predictive model need to be further defined in large clinical studies.
Impact: Salivary proteomic and transcriptomic biomarkers can discriminate oral cancer from control subjects. Cancer Epidemiol Biomarkers Prev; 21(4); 664–72. ©2012 AACR. |
---|---|
AbstractList | Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three proteins previously reported as biomarkers are capable of discriminating patients with oral squamous cell carcinomas (OSCC) from healthy subjects in independent cohorts and by a National Cancer Institute (NCI)-Early Detection Research Network (EDRN)-Biomarker Reference Laboratory (BRL).BACKGROUNDOral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three proteins previously reported as biomarkers are capable of discriminating patients with oral squamous cell carcinomas (OSCC) from healthy subjects in independent cohorts and by a National Cancer Institute (NCI)-Early Detection Research Network (EDRN)-Biomarker Reference Laboratory (BRL).Three hundred and ninety-five subjects from five independent cohorts based on case controlled design were investigated by two independent laboratories, University of California, Los Angeles (Los Angeles, CA) discovery laboratory and NCI-EDRN-BRL.METHODSThree hundred and ninety-five subjects from five independent cohorts based on case controlled design were investigated by two independent laboratories, University of California, Los Angeles (Los Angeles, CA) discovery laboratory and NCI-EDRN-BRL.Expression of all seven mRNA and three protein markers was increased in OSCC versus controls in all five cohorts. With respect to individual marker performance across the five cohorts, the increase in interleukin (IL)-8 and subcutaneous adipose tissue (SAT) was statistically significant and they remained top performers across different cohorts in terms of sensitivity and specificity. A previously identified multiple marker model showed an area under the receiver operating characteristic (ROC) curve for prediction of OSCC status ranging from 0.74 to 0.86 across the cohorts.RESULTSExpression of all seven mRNA and three protein markers was increased in OSCC versus controls in all five cohorts. With respect to individual marker performance across the five cohorts, the increase in interleukin (IL)-8 and subcutaneous adipose tissue (SAT) was statistically significant and they remained top performers across different cohorts in terms of sensitivity and specificity. A previously identified multiple marker model showed an area under the receiver operating characteristic (ROC) curve for prediction of OSCC status ranging from 0.74 to 0.86 across the cohorts.The validation of these biomarkers showed their feasibility in the discrimination of OSCCs from healthy controls. Established assay technologies are robust enough to perform independently. Individual cutoff values for each of these markers and for the combined predictive model need to be further defined in large clinical studies.CONCLUSIONSThe validation of these biomarkers showed their feasibility in the discrimination of OSCCs from healthy controls. Established assay technologies are robust enough to perform independently. Individual cutoff values for each of these markers and for the combined predictive model need to be further defined in large clinical studies.Salivary proteomic and transcriptomic biomarkers can discriminate oral cancer from control subjects.IMPACTSalivary proteomic and transcriptomic biomarkers can discriminate oral cancer from control subjects. Background: Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three proteins previously reported as biomarkers are capable of discriminating patients with oral squamous cell carcinomas (OSCC) from healthy subjects in independent cohorts and by a National Cancer Institute (NCI)-Early Detection Research Network (EDRN)-Biomarker Reference Laboratory (BRL). Methods: Three hundred and ninety-five subjects from five independent cohorts based on case controlled design were investigated by two independent laboratories, University of California, Los Angeles (Los Angeles, CA) discovery laboratory and NCI-EDRN-BRL. Results: Expression of all seven mRNA and three protein markers was increased in OSCC versus controls in all five cohorts. With respect to individual marker performance across the five cohorts, the increase in interleukin (IL)-8 and subcutaneous adipose tissue (SAT) was statistically significant and they remained top performers across different cohorts in terms of sensitivity and specificity. A previously identified multiple marker model showed an area under the receiver operating characteristic (ROC) curve for prediction of OSCC status ranging from 0.74 to 0.86 across the cohorts. Conclusions: The validation of these biomarkers showed their feasibility in the discrimination of OSCCs from healthy controls. Established assay technologies are robust enough to perform independently. Individual cutoff values for each of these markers and for the combined predictive model need to be further defined in large clinical studies. Impact: Salivary proteomic and transcriptomic biomarkers can discriminate oral cancer from control subjects. Cancer Epidemiol Biomarkers Prev; 21(4); 664–72. ©2012 AACR. Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three proteins previously reported as biomarkers are capable of discriminating patients with oral squamous cell carcinomas (OSCC) from healthy subjects in independent cohorts and by a National Cancer Institute (NCI)-Early Detection Research Network (EDRN)-Biomarker Reference Laboratory (BRL). Three hundred and ninety-five subjects from five independent cohorts based on case controlled design were investigated by two independent laboratories, University of California, Los Angeles (Los Angeles, CA) discovery laboratory and NCI-EDRN-BRL. Expression of all seven mRNA and three protein markers was increased in OSCC versus controls in all five cohorts. With respect to individual marker performance across the five cohorts, the increase in interleukin (IL)-8 and subcutaneous adipose tissue (SAT) was statistically significant and they remained top performers across different cohorts in terms of sensitivity and specificity. A previously identified multiple marker model showed an area under the receiver operating characteristic (ROC) curve for prediction of OSCC status ranging from 0.74 to 0.86 across the cohorts. The validation of these biomarkers showed their feasibility in the discrimination of OSCCs from healthy controls. Established assay technologies are robust enough to perform independently. Individual cutoff values for each of these markers and for the combined predictive model need to be further defined in large clinical studies. Salivary proteomic and transcriptomic biomarkers can discriminate oral cancer from control subjects. |
Author | Le, Anh Xiao, Hua Lingen, Mark Kastratovic, Dragana A. Henson, Bradley Wang, Jianghua Reiss, Jean Zhou, Hui Abemayor, Elliot Chia, David Morris, Darly Hu, Shen Wong, David T.W. Randolph, Timothy Feng, Ziding Messadi, Diana Wang, Marilene Arellano, Martha Nabili, Vishad Sinha, Uttam Elashoff, David Akin, David |
Author_xml | – sequence: 1 givenname: David surname: Elashoff fullname: Elashoff, David – sequence: 2 givenname: Hui surname: Zhou fullname: Zhou, Hui – sequence: 3 givenname: Jean surname: Reiss fullname: Reiss, Jean – sequence: 4 givenname: Jianghua surname: Wang fullname: Wang, Jianghua – sequence: 5 givenname: Hua surname: Xiao fullname: Xiao, Hua – sequence: 6 givenname: Bradley surname: Henson fullname: Henson, Bradley – sequence: 7 givenname: Shen surname: Hu fullname: Hu, Shen – sequence: 8 givenname: Martha surname: Arellano fullname: Arellano, Martha – sequence: 9 givenname: Uttam surname: Sinha fullname: Sinha, Uttam – sequence: 10 givenname: Anh surname: Le fullname: Le, Anh – sequence: 11 givenname: Diana surname: Messadi fullname: Messadi, Diana – sequence: 12 givenname: Marilene surname: Wang fullname: Wang, Marilene – sequence: 13 givenname: Vishad surname: Nabili fullname: Nabili, Vishad – sequence: 14 givenname: Mark surname: Lingen fullname: Lingen, Mark – sequence: 15 givenname: Darly surname: Morris fullname: Morris, Darly – sequence: 16 givenname: Timothy surname: Randolph fullname: Randolph, Timothy – sequence: 17 givenname: Ziding surname: Feng fullname: Feng, Ziding – sequence: 18 givenname: David surname: Akin fullname: Akin, David – sequence: 19 givenname: Dragana A. surname: Kastratovic fullname: Kastratovic, Dragana A. – sequence: 20 givenname: David surname: Chia fullname: Chia, David – sequence: 21 givenname: Elliot surname: Abemayor fullname: Abemayor, Elliot – sequence: 22 givenname: David T.W. surname: Wong fullname: Wong, David T.W. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25777198$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22301830$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kV1LwzAYhYNM3Kb-BKU34lVn0iRNgyDonDoYbKBehzRNINo1M-kG-_embkPwwqt88Jw3OecMQa9xjQbgAsERQrS4QZDSlPOcjiaLaYpQiiDHR2CAKC5Sxijtxf2B6YNhCB8QQsYpPQH9LMMQFRgOwN3C642sbSVb65rEmeQ1njbSb5MH65bSf2ofEuN8MveyTsayUdonj7rVqhOcgWMj66DP9-speH-avI1f0tn8eTq-n6WKUNSmZVllmBnGCGZEc5izjLBKac6R4hoxrTAvuWKGqPj9sjJcZSaTeVYiGCdIfAqud3NX3n2tdWjF0gal61o22q2D4DkmHHNCInm5J9flUldi5W10sRUHyxG42gMyKFkbHy3Z8MtRxhjiReRud5zyLgSvjVC2_Ump9dLWAkHRFSG6kEUXsohFxCvRFRHV9I_68MD_um8Gf4qa |
CODEN | CEBPE4 |
CitedBy_id | crossref_primary_10_2174_0118715257269271231201094946 crossref_primary_10_3390_diagnostics11071287 crossref_primary_10_3390_ijms252413514 crossref_primary_10_1254_fpj_141_302 crossref_primary_10_3390_cancers12082273 crossref_primary_10_1002_jcb_26042 crossref_primary_10_1186_gm383 crossref_primary_10_2341_12_143_BL crossref_primary_10_3892_ol_2018_9168 crossref_primary_10_1186_s13027_016_0093_6 crossref_primary_10_1016_j_oraloncology_2015_06_010 crossref_primary_10_1016_j_jebdp_2013_10_006 crossref_primary_10_1007_s00784_015_1488_2 crossref_primary_10_1136_flgastro_2016_100712 crossref_primary_10_1002_pmic_201200533 crossref_primary_10_1016_j_ajoms_2021_02_003 crossref_primary_10_1111_jog_13576 crossref_primary_10_3390_ma12040654 crossref_primary_10_14219_jada_archive_2012_0339 crossref_primary_10_1016_j_clinthera_2015_02_017 crossref_primary_10_1016_j_aca_2020_03_043 crossref_primary_10_1002_jbio_201500204 crossref_primary_10_1080_03610926_2018_1433849 crossref_primary_10_1016_j_archoralbio_2017_12_003 crossref_primary_10_14219_jada_archive_2012_0340 crossref_primary_10_1615_CritRevOncog_2022047079 crossref_primary_10_2116_analsci_31_73 crossref_primary_10_1016_j_jobcr_2015_08_006 crossref_primary_10_1080_14737159_2018_1523008 crossref_primary_10_1155_2013_813756 crossref_primary_10_1080_01635581_2018_1521439 crossref_primary_10_18231_j_jdp_2023_002 crossref_primary_10_4137_BIC_S25375 crossref_primary_10_3390_cancers6031522 crossref_primary_10_1016_j_oraloncology_2015_08_015 crossref_primary_10_1016_j_canep_2016_04_011 crossref_primary_10_1177_0022034513487209 crossref_primary_10_3390_cells12141916 crossref_primary_10_12688_f1000research_22941_1 crossref_primary_10_1186_1471_2288_14_37 crossref_primary_10_1002_hed_26526 crossref_primary_10_1111_jop_13299 crossref_primary_10_1038_nrclinonc_2012_20 crossref_primary_10_3390_diagnostics10100818 crossref_primary_10_1177_1559827615569707 crossref_primary_10_1080_14737159_2024_2340997 crossref_primary_10_1016_j_oor_2024_100503 crossref_primary_10_1016_j_oraloncology_2020_104720 crossref_primary_10_2217_bmm_2021_0370 crossref_primary_10_1016_j_oraloncology_2017_05_016 crossref_primary_10_1186_s12903_024_04840_3 crossref_primary_10_3109_07357907_2015_1041642 crossref_primary_10_1016_j_oraloncology_2014_09_005 crossref_primary_10_1111_joor_12664 crossref_primary_10_5507_bp_2016_062 crossref_primary_10_1096_fj_201600984R crossref_primary_10_1177_1179299X17732007 crossref_primary_10_1016_j_bios_2021_113698 crossref_primary_10_3390_ijms16048676 crossref_primary_10_1016_j_bios_2016_02_040 crossref_primary_10_5125_jkaoms_2020_46_5_301 crossref_primary_10_1016_j_oraloncology_2015_10_007 crossref_primary_10_17656_sdj_10067 crossref_primary_10_1371_journal_pone_0177282 crossref_primary_10_3390_biomedicines12061150 crossref_primary_10_1038_s41598_024_75735_0 crossref_primary_10_1186_s12943_019_1021_3 crossref_primary_10_1038_srep31520 crossref_primary_10_1016_j_oraloncology_2016_07_013 crossref_primary_10_1146_annurev_anchem_061020_123959 crossref_primary_10_4236_abb_2020_115015 crossref_primary_10_3389_fpubh_2017_00077 crossref_primary_10_1002_cncr_27700 crossref_primary_10_1007_s00784_013_1041_0 crossref_primary_10_1016_j_bios_2021_112995 crossref_primary_10_1186_s13046_023_02743_9 crossref_primary_10_7717_peerj_12715 crossref_primary_10_1007_s12663_024_02365_4 crossref_primary_10_3389_fonc_2022_828434 crossref_primary_10_1002_med_21646 crossref_primary_10_1080_14737159_2017_1404906 crossref_primary_10_1038_s41598_020_64494_3 crossref_primary_10_1007_s40496_014_0014_y crossref_primary_10_2144_000114254 crossref_primary_10_1016_j_humimm_2014_11_002 crossref_primary_10_1016_j_bj_2023_04_002 crossref_primary_10_1111_jop_12895 crossref_primary_10_1111_prd_12099 crossref_primary_10_1111_jre_12407 crossref_primary_10_1007_s11033_020_05659_1 crossref_primary_10_1021_acs_analchem_1c00410 crossref_primary_10_1074_jbc_M115_692640 crossref_primary_10_1021_pr500038k crossref_primary_10_4103_jms_jms_90_23 crossref_primary_10_1016_j_urolonc_2016_12_007 crossref_primary_10_1002_sim_6811 crossref_primary_10_1016_j_ijom_2017_09_016 crossref_primary_10_1016_j_bcp_2013_08_026 crossref_primary_10_3109_00016357_2015_1110249 crossref_primary_10_4103_0973_029X_325237 crossref_primary_10_1371_journal_pone_0158462 crossref_primary_10_1007_s12253_017_0296_1 crossref_primary_10_1089_omi_2015_0174 crossref_primary_10_1097_MOO_0000000000000502 crossref_primary_10_1186_s12885_021_07932_3 crossref_primary_10_1186_2001_1326_3_3 crossref_primary_10_1158_1078_0432_CCR_15_1761 crossref_primary_10_5402_2012_931301 crossref_primary_10_1016_j_job_2014_06_001 crossref_primary_10_3390_ijms241713657 crossref_primary_10_18231_j_jdpo_2024_016 crossref_primary_10_1186_s13063_015_0951_3 crossref_primary_10_18632_oncotarget_4181 crossref_primary_10_1016_j_oooo_2016_08_021 crossref_primary_10_3390_ijms251910596 crossref_primary_10_1080_01478885_2020_1861918 crossref_primary_10_1158_1940_6207_CAPR_15_0200 crossref_primary_10_1111_jop_13003 crossref_primary_10_3390_cancers12082009 crossref_primary_10_1038_s41368_022_00209_w crossref_primary_10_1373_clinchem_2018_290569 crossref_primary_10_1002_hed_24958 crossref_primary_10_1177_1535370216681550 crossref_primary_10_1186_s12957_021_02423_y |
Cites_doi | 10.1002/ijc.22369 10.1002/jcb.20784 10.1002/hed.20392 10.1002/pmic.200401133 10.1373/clinchem.2007.096164 10.1158/1078-0432.CCR-06-2945 10.1002/art.22954 10.1093/jnci/djn326 10.1158/1078-0432.CCR-05-2412 10.1158/1055-9965.EPI-04-0546 10.1158/1078-0432.CCR-04-1167 10.14219/jada.archive.2010.0223 10.1158/1078-0432.CCR-07-5037 10.1371/journal.pone.0005875 10.1016/j.jprot.2008.04.004 10.1177/154405910408300303 10.1373/49.1.1 |
ContentType | Journal Article |
Copyright | 2015 INIST-CNRS 2012 AACR. |
Copyright_xml | – notice: 2015 INIST-CNRS – notice: 2012 AACR. |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1158/1055-9965.EPI-11-1093 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-7755 |
EndPage | 672 |
ExternalDocumentID | 22301830 25777198 10_1158_1055_9965_EPI_11_1093 |
Genre | Comparative Study Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | Los Angeles |
GeographicLocations_xml | – name: Los Angeles |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA015704 – fundername: NCI NIH HHS grantid: R21 CA126733 – fundername: NIDCR NIH HHS grantid: U01 DE016275 – fundername: NIDCR NIH HHS grantid: R01 DE017170 – fundername: NCI NIH HHS grantid: R21CA126733 – fundername: NIDCR NIH HHS grantid: U01DE016275 – fundername: NIDCR NIH HHS grantid: R01DE017170 |
GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5VS 6J9 AAFWJ AAYXX ABOCM ACPRK ADBBV ADCOW AENEX AFHIN AFRAH ALMA_UNASSIGNED_HOLDINGS BR6 BTFSW CITATION CS3 DIK DU5 E3Z EBS EJD F5P FRP H13 IH2 KQ8 L7B OK1 P2P PQQKQ QTD RCR RHI SJN UDS W8F WOQ .55 3O- AI. C1A H~9 IQODW VH1 WHG X7M ZXP CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c451t-bbd237f774374e9067247dce991c9e17ec39b9c7f4c538bdf9c2f2a62b10c45a3 |
ISSN | 1055-9965 1538-7755 |
IngestDate | Fri Jul 11 06:39:14 EDT 2025 Mon Jul 21 06:06:23 EDT 2025 Mon Jul 21 09:16:26 EDT 2025 Tue Jul 01 04:31:24 EDT 2025 Thu Apr 24 23:01:40 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Oral cancer Stomatology Biological marker Biological indicator Malignant tumor Oral cavity Salivary gland disease Cancerology Salivary gland cancer Oral cavity disease Diagnosis Detection Cancer |
Language | English |
License | CC BY 4.0 2012 AACR. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c451t-bbd237f774374e9067247dce991c9e17ec39b9c7f4c538bdf9c2f2a62b10c45a3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://aacrjournals.org/cebp/article-pdf/21/4/664/2275033/664.pdf |
PMID | 22301830 |
PQID | 963493944 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_963493944 pubmed_primary_22301830 pascalfrancis_primary_25777198 crossref_citationtrail_10_1158_1055_9965_EPI_11_1093 crossref_primary_10_1158_1055_9965_EPI_11_1093 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2012-04-01 |
PublicationDateYYYYMMDD | 2012-04-01 |
PublicationDate_xml | – month: 04 year: 2012 text: 2012-04-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Philadelphia, PA |
PublicationPlace_xml | – name: Philadelphia, PA – name: United States |
PublicationTitle | Cancer epidemiology, biomarkers & prevention |
PublicationTitleAlternate | Cancer Epidemiol Biomarkers Prev |
PublicationYear | 2012 |
Publisher | American Association for Cancer Research |
Publisher_xml | – name: American Association for Cancer Research |
References | Hu (2022060920125095100_bib11) 2007; 56 Bossuyt (2022060920125095100_bib19) 2003; 49 Franzmann (2022060920125095100_bib3) 2005; 14 Gao (2022060920125095100_bib20) 2009; 4 Houali (2022060920125095100_bib4) 2007; 13 Ulmer (2022060920125095100_bib14) 2006; 98 Li (2022060920125095100_bib12) 2004; 83 Cooper (2022060920125095100_bib18) 1994 Dowling (2022060920125095100_bib2) 2008; 71 Spafford (2022060920125095100_bib9) 2001; 7 Park (2022060920125095100_bib15) 2007; 120 Li (2022060920125095100_bib7) 2004; 10 Hu (2022060920125095100_bib13) 2008; 54 Rosas (2022060920125095100_bib8) 2001; 61 Franzmann (2022060920125095100_bib10) 2006; 28 Pepe (2022060920125095100_bib21) 2008; 100 Hu (2022060920125095100_bib5) 2008; 14 Rethman (2022060920125095100_bib1) 2010; 141 Marchetti (2022060920125095100_bib16) 2002; 62 Wu (2022060920125095100_bib17) 2005; 5 Nagler (2022060920125095100_bib6) 2006; 12 |
References_xml | – volume: 61 start-page: 939 year: 2001 ident: 2022060920125095100_bib8 article-title: Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients publication-title: Cancer Res – volume: 120 start-page: 813 year: 2007 ident: 2022060920125095100_bib15 article-title: Up-regulation of Mac-2 binding protein by hTERT in gastric cancer. publication-title: Int J Cancer doi: 10.1002/ijc.22369 – volume: 98 start-page: 1351 year: 2006 ident: 2022060920125095100_bib14 article-title: Tumor-associated antigen 90K/Mac-2-binding protein: possible role in colon cancer publication-title: J Cell Biochem doi: 10.1002/jcb.20784 – volume: 28 start-page: 663 year: 2006 ident: 2022060920125095100_bib10 article-title: Complete hypopharyngeal obstruction by mucosal adhesions: a complication of intensive chemoradiation for advanced head and neck cancer publication-title: Head Neck doi: 10.1002/hed.20392 – volume: 7 start-page: 607 year: 2001 ident: 2022060920125095100_bib9 article-title: Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis publication-title: Clin Cancer Res – volume: 5 start-page: 3173 year: 2005 ident: 2022060920125095100_bib17 article-title: Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model publication-title: Proteomics doi: 10.1002/pmic.200401133 – volume: 54 start-page: 824 year: 2008 ident: 2022060920125095100_bib13 article-title: DTW Exon-level expression profiling: a comprehensive transcriptome analysis of oral fluids publication-title: Clin Chem doi: 10.1373/clinchem.2007.096164 – volume: 13 start-page: 4993 year: 2007 ident: 2022060920125095100_bib4 article-title: A new diagnostic marker for secreted Epstein-Barr virus encoded LMP1 and BARF1 oncoproteins in the serum and saliva of patients with nasopharyngeal carcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2945 – volume: 62 start-page: 2535 year: 2002 ident: 2022060920125095100_bib16 article-title: Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients publication-title: Cancer Res – volume: 56 start-page: 3588 year: 2007 ident: 2022060920125095100_bib11 article-title: Salivary proteomic and genomic biomarkers for primary Sjogren's syndrome publication-title: Arthritis Rheum doi: 10.1002/art.22954 – year: 1994 ident: 2022060920125095100_bib18 article-title: The handbook of research synthesis – volume: 100 start-page: 1432 year: 2008 ident: 2022060920125095100_bib21 article-title: Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djn326 – volume: 12 start-page: 3979 year: 2006 ident: 2022060920125095100_bib6 article-title: Concomitant analysis of salivary tumor markers–a new diagnostic tool for oral cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-2412 – volume: 14 start-page: 735 year: 2005 ident: 2022060920125095100_bib3 article-title: Salivary soluble CD44: a potential molecular marker for head and neck cancer publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-04-0546 – volume: 10 start-page: 8442 year: 2004 ident: 2022060920125095100_bib7 article-title: Salivary transcriptome diagnostics for oral cancer detection publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-1167 – volume: 141 start-page: 509 year: 2010 ident: 2022060920125095100_bib1 article-title: Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas publication-title: J Am Dent Assoc doi: 10.14219/jada.archive.2010.0223 – volume: 14 start-page: 6246 year: 2008 ident: 2022060920125095100_bib5 article-title: Salivary proteomics for oral cancer biomarker discovery publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-5037 – volume: 4 start-page: e5875 year: 2009 ident: 2022060920125095100_bib20 article-title: Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer publication-title: PLoS One doi: 10.1371/journal.pone.0005875 – volume: 71 start-page: 168 year: 2008 ident: 2022060920125095100_bib2 article-title: Analysis of the saliva proteome from patients with head and neck squamous cell carcinoma reveals differences in abundance levels of proteins associated with tumour progression and metastasis publication-title: J Proteomics doi: 10.1016/j.jprot.2008.04.004 – volume: 83 start-page: 199 year: 2004 ident: 2022060920125095100_bib12 article-title: RNA profiling of cell-free saliva using microarray technology publication-title: J Dent Res doi: 10.1177/154405910408300303 – volume: 49 start-page: 1 year: 2003 ident: 2022060920125095100_bib19 article-title: Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy publication-title: Clin Chem doi: 10.1373/49.1.1 |
SSID | ssj0007955 |
Score | 2.4511538 |
Snippet | Background: Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early... Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection... |
SourceID | proquest pubmed pascalfrancis crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 664 |
SubjectTerms | Adult Aged Biological and medical sciences Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Carcinoma, Squamous Cell - diagnosis Carcinoma, Squamous Cell - genetics Carcinoma, Squamous Cell - metabolism Case-Control Studies Enzyme-Linked Immunosorbent Assay Feasibility Studies Female Follow-Up Studies Genotype Humans Interleukin-8 - metabolism Los Angeles Male Medical sciences Middle Aged Mouth Neoplasms - diagnosis Mouth Neoplasms - genetics Mouth Neoplasms - metabolism Neoplasm Proteins - metabolism Otorhinolaryngology. Stomatology Prognosis Real-Time Polymerase Chain Reaction Retrospective Studies RNA, Messenger - genetics Saliva - chemistry Tumors Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology |
Title | Prevalidation of Salivary Biomarkers for Oral Cancer Detection |
URI | https://www.ncbi.nlm.nih.gov/pubmed/22301830 https://www.proquest.com/docview/963493944 |
Volume | 21 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Ja9wwFBbTFEqhhO6dLkGH3oqnY1u2rEuhhJQ00I0mNDcjyXITSOxhxj60P6G_Ou9JGtnTpkt6MYMHPRu9z2_R2wh5HmO5ZFFlEU9rHjGdiEhJmYCXUkilagFWrM3yfZ_vH7GD4-x4MvkxylrqOzXT3y-tK_kfrsI94CtWyV6Bs4Eo3IDfwF-4Aofh-k88xv5LYEdXwez7LDGys_yGIybPMfFmadstvPiAZfi7yOAlSJjOpl81Y7vU_2eGebF289VABiGy8P2e2lHKh1ydtK6z4yg9Hg-i296qtf40xHTM6cpXjw2Q_OLPqw8Apl9Pejk-hcB0jpC84gTnPMsi8J1chNoMwpRz14Z3LW2TeIQqNhKduetm7rVw7gb6_Crgs8KeNfinzfY-vo1sUp6bs7jZUPsnRRfSD63jkxUlkimRTAlk4BaG49Nr5HrCwQ7DAP-nofM8F3aCbniyrwYDMi8vfZsNO-fWQq7gk6vdrJTfOzPWqDm8Tba9N0JfO2jdIRPT3CU33vl8i3vk1QbCaFvTNcLogDAKCKOIMOpQRAPC7pOjN3uHu_uRn7gRaZbFXaRUlaS8Bpcg5cwIDNMzXmkDToQWJuZGp0IJzWumgbeqqoVO6kTmiYrnQEGmD8hW0zbmEaHzCkcLqFTHPGZZLSR4xkVVKK3AhE91PiVsvT-l9u3ocSrKWflH7kzJLCxbuH4sf1uws7H5YRXoKs5jUUwJXXOjBNGK8TLZmLZflaCbmMDC8Sl56Lg0LAbPHZTh_PFVX-cJuTl8Pk_JVrfszTMwazu1Y_F2AaN0mUU |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevalidation+of+Salivary+Biomarkers+for+Oral+Cancer+Detection&rft.jtitle=Cancer+epidemiology%2C+biomarkers+%26+prevention&rft.au=Elashoff%2C+David&rft.au=Zhou%2C+Hui&rft.au=Reiss%2C+Jean&rft.au=Wang%2C+Jianghua&rft.date=2012-04-01&rft.issn=1055-9965&rft.eissn=1538-7755&rft.volume=21&rft.issue=4&rft.spage=664&rft.epage=672&rft_id=info:doi/10.1158%2F1055-9965.EPI-11-1093&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_1055_9965_EPI_11_1093 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1055-9965&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1055-9965&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1055-9965&client=summon |